Georgina Pamela Coló | Gene Therapy | Best Researcher Award

Georgina Pamela Coló | Gene Therapy | Best Researcher Award

Dr. Georgina Pamela Coló, INIBIBB-CONICET, Argentina

Dr. Georgina Pamela Coló is a distinguished molecular biologist specializing in cancer research. She earned her Ph.D. in Molecular Biology from the University of Buenos Aires (2007, Summa Cum Laude) and holds an MS in Biotechnology from Quilmes National University. Currently a Scientific Researcher at CONICET’s Instituto de Investigaciones Bioquímicas (INIBIBB) in Argentina, she also leads a Max Planck Institute partner group. Her research focuses on cancer progression and therapeutic innovations. With extensive international experience in Germany, Spain, and the U.S., Dr. Coló has authored impactful publications in top-tier journals.

Publication Profile

Scopus

Education

Dr. Georgina Pamela Coló 🎓 is a distinguished molecular biologist with a Ph.D. from the University of Buenos Aires, School of Sciences (2003-2007), where she graduated summa cum laude (10/10) under the mentorship of Dr. M.A. Costas. Prior to her doctorate, she earned an M.S. in Biotechnology (8.74/10) from Quilmes National University (1998-2002). Her academic journey began with a B.Sc. in Science and Technology (1998-2000) and training as a Laboratory Technician 🔬. With a strong foundation in biotechnology and molecular biology, Dr. Coló has made significant contributions to scientific research and innovation. 🧬✨

Experience

Dr. Georgina Pamela Coló 🧬 is a dedicated cancer researcher currently serving as a Scientific Researcher at CONICET (2024-present) at the Instituto de Investigaciones Bioquímicas (INIBIBB), Argentina. She previously worked as an Assistant Researcher (2019-2024) under Dr. Curino. Since 2018, she has led a Max-Planck-Institute partner group 🇩🇪 with Dr. Prof. Reinhard Fässler. Her career includes research fellowships in Spain 🇪🇸 and Germany, as well as postdoctoral studies at INIBIBB, Max-Planck-Institute, and CIB-CSIC. With extensive experience in molecular medicine and cancer biology 🔬, Dr. Coló continues to make groundbreaking contributions to biomedical research. ✨

Awards

Dr. Georgina Pamela Coló 🏆 has received numerous prestigious awards for her outstanding contributions to biomedical research. In 2021, she won the Best Poster Award 🖼️ at the Reunión de Sociedades de Biociencias in Argentina. She was honored with the JCI TOYP Award (2020) for scientific and technological development. In 2019, she received the Lucio Cherny Award for interdisciplinary research 🧬. Her accolades include the Best Poster Award (2018), multiple CONICET fellowships 🎓, and the Max Planck postdoctoral fellowship (2013-2016). Dr. Coló’s impactful research continues to be recognized on both national and international levels.

Research Focus

Dr. Georgina Pamela Coló is a researcher specializing in nanomedicine 🧪, oncology 🎗️, and proteomics 🧬. Her work focuses on amorphous silica nanoparticles and their antitumor activity in triple-negative breast cancer cells 🏥. She also investigates the proteomic effects of hemin in breast cancer, exploring molecular pathways and therapeutic targets. Her research integrates nanotechnology 🏗️ and biochemistry to develop innovative cancer treatments. Through cutting-edge proteomic analysis, she contributes to personalized medicine and targeted drug delivery 🎯. Her studies are highly relevant to pharmaceutical sciences 💊 and biomedical research 🔬, advancing potential cancer therapies.

Publication Top Notes

Amorphous silica nanoparticles exhibit antitumor activity in triple-negative breast cancer cells

Proteomic analysis of the effect of hemin in breast cancer

SON DINH PHONG | Gene Therapy | Best Researcher Award

SON DINH PHONG | Gene Therapy | Best Researcher Award

Dr SON DINH PHONG, DUYTAN UNIVERSITY, Vietnam

Dr. Dinh Phong Son is a dedicated researcher in molecular medicine at Duy Tan University, Vietnam. With a Ph.D. from Guangxi Medical University, China, and a background in laboratory medicine from Hue University of Medicine and Pharmacy, his research focuses on molecular biomarkers for early disease detection 🧪🔬. He explores the LncRNA/CircRNA/miRNA/gene/protein-drug interaction network and gene-editing techniques like CRISPR/Cas9 for targeted therapy. His work on cardiovascular disease and cancer diagnostics has been published in prestigious journals 📚🧑‍🔬. Passionate about advancing molecular biology, he aspires to contribute to innovative breakthroughs in disease research.

Publication Profile

orcid

Education

Dr. Dinh Phong Son 🎓 holds a degree in Laboratory Medicine Technique from Hue University of Medicine and Pharmacy, Vietnam, and a Ph.D. in Molecular Medicine from Guangxi Medical University, China. 🧬 His expertise lies in molecular biology, with a strong focus on disease biomarkers and gene-targeted therapies. 🏥🔬 With a solid academic foundation, he has contributed significantly to scientific advancements, particularly in precision medicine and diagnostics. His research aims to enhance medical treatments by identifying key genetic markers, paving the way for innovative therapeutic approaches. 🌍✨ Dr. Son’s dedication to science continues to drive breakthroughs in healthcare. 💡👨‍⚕️

Research and Innovations

Dr. Son Dinh Phong 🔬 is deeply engaged in advancing molecular biology through next-generation sequencing and online medical databases. His primary focus is identifying potential biomarkers for early disease detection, including diabetes, cardiovascular diseases, stroke, and cancer. 🧬🩺 His research also explores gene-targeted therapies, utilizing CRISPR/Cas9 for gene editing, overexpression, and silencing. 🏥 His studies on LncRNA/CircRNA/miRNA/gene/protein-drug interaction networks provide a foundation for future medical breakthroughs. 📊✨ Committed to innovation, Dr. Son’s ongoing work (2023-2025) aims to drive scientific progress, hoping for greater support to expand molecular biology research worldwide. 🌍💡

Research Contributions

Dr. Son Dinh Phong 🔬 is highly proficient in advanced molecular biology techniques, including PCR, qPCR, and sequencing analysis 🧪🧬. He specializes in CRISPR/Cas9 genome editing, RNA silencing, and overexpression assays, contributing to groundbreaking gene therapy research. 🏥 His expertise also includes cell culture, western blotting, and fluorescence in situ hybridization, essential for studying gene expression and protein interactions. 🔍🧫 Additionally, he excels in bioinformatics and molecular docking simulations, enabling in-depth analysis of gene interactions and drug responses. 💻💊 With a strong foundation in computational biology, Dr. Son continues to drive innovation in precision medicine and molecular diagnostics. 🚀✨

Editorial Appointments

Dr. Son Dinh Phong 🌍🔬 actively contributes to the global scientific community through his extensive research and publications. While specific editorial roles, consultancy projects, or industry collaborations may not be listed, his scholarly work reflects deep engagement in molecular biology and precision medicine. 🧬📖 His ORCID profile further validates his impactful contributions, showcasing his dedication to advancing medical research. 🏥✨ Through collaborations and scientific discourse, Dr. Son continues to push the boundaries of innovation, striving to enhance disease diagnostics and therapeutic strategies. His commitment to research ensures lasting contributions to the ever-evolving field of molecular medicine. 💡🚀

Research Focus

Dr. Son Dinh Phong’s research primarily focuses on cardiovascular diseases 🫀, non-coding RNAs 🧬, and bioinformatics-driven biomarker discovery 🖥️. His work explores circular RNAs (circRNAs) and microRNAs (miRNAs) in coronary heart disease (CHD) 🏥, revealing their role as competing endogenous RNAs (ceRNAs) in gene regulation. Additionally, he investigates serum miRNAs as potential diagnostic biomarkers for various cancers 🎗️ and employs computational approaches 🔬 to identify key regulatory networks in diseases like latent tuberculosis 🦠. His studies integrate molecular biology, genomics, and systems biology to advance precision medicine 🎯 and therapeutic innovations 💊 for complex diseases.

Publication Top Notes